Under single-patient expanded access program, seven patients with serious and life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01 in 2017. Company plans to present topline results in early 2018 Company expects to continue its expanded access clinical strategy in 2018, review data with FDA in mid-2018 and initiate Phase 2 or […]
Posted on 01/12/2017 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]
Avita Announces Office Transitions in Australia and the UK Decision Optimizes Access to Strategic Markets to Support Long-Term Growth Strategy Valencia, CA, USA, Perth, Australia and London, United Kingdom, 29 November 2017 — Avita Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company with a platform technology creating opportunities in burn and wound care, and […]
Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia Second clinical institution to treat patients with AB-SA01 or AB-PA01 under expanded access is now operational First-in-human intravenous dosing of AB-SA01 as part of expanded access treatment of a patient […]
Avita Medical announces Rights Issue raises $12.4 million Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the results of the Non-Renounceable Rights Issue. The Board of Avita Medical Limited is pleased […]
Valencia, CA, USA, Perth, Australia and London, United Kingdom, 21 September 2017 — Avita Medical (ASX: AVH), (OTCQX: AVMXY), – link here a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes […]
Adherium today announced it has released SmartTurbo Model 4, the next generation of the company’s adherence monitoring technology, for AstraZeneca’s Turbuhaler medication. SmartTurbo Model 4 includes usability improvements to make the installation and removal of the Turbuhaler easier for older patients with COPD. The device also features a series of new larger buttons that help patients easily access new optional […]
A patient suffering from a life-threatening staphylococcal endocarditis received AB-SA01 under expanded access regulatory guidelines CATEGORY: Featured Monday, September 11, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We continue implementation of our strategy to work with leading infectious disease physicians in the United States and Australia and […]
Wednesday, September 6, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “The R&D tax rebate is an important source of non-dilutive capital and we appreciate the Australian government’s support as we develop our novel bacteriophage therapies aimed at combatting the growing global threat of antibiotic resistance” SAN DIEGO–(BUSINESS […]
04 Sep 2017 – link here We’re thrilled to announce that Adherium has received U.S. Food and Drug Administration (FDA) 510(K) clearance for its new SmartTouch for Symbicort® inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler. The SmartTouch for Symbicort® is a device installed onto a patient’s inhaler to monitor and encourage medication adherence as part of a self-management […]